Pharmaceutical companies have been trying to find a way to prevent the spread of cancer for decades.
But the best and most effective way has been with a pill that prevents the growth of cancer cells.
That is the case for a new drug from Vertex Pharmaceuticals, which has been approved by the Food and Drug Administration (FDA) for the treatment of certain types of cancer.
The drug, called VXO, is part of an ongoing trial by the National Cancer Institute that aims to determine if the drug is safe and effective in patients with relapsed or relapsing-remitting forms of the disease.
The company says it is currently recruiting about 1,200 patients and that the clinical trial will be completed in 2021.
This is the first time that Vertex has made a drug approved for the prevention of cancer in patients.
Vertex is also a leader in the development of a new type of cancer therapy called immunotherapy, which uses a vaccine to prevent cancer cells from replicating.
Vertes vaccines are the only approved cancer vaccine currently available to patients in the United States.
Veritas vaccines are also designed to fight the deadly disease known as T-cell leukemia, which is caused by a subset of a gene called T-cells.
In T-Cell leukemia, cancer cells can be genetically targeted to develop and invade healthy tissue.
While the T-helper gene is a crucial part of normal T-lymphocyte development, it has been shown to be mutated in people with relapsed-remittent forms of T- cell leukemia, making them unable to grow in the immune system and causing cancer.
While cancer treatments typically include immune-boosting drugs that attack T- cells, the drugs also often contain antibodies that can help kill cancer cells before they can replicate.
The combination of a vaccine and a vaccine-based treatment can help prevent the progression of T and/or B cell cancers, says Michael Smith, director of clinical research at Vertex.
“We’re really excited about this vaccine because we’re developing an immunotherapy vaccine to treat patients with T- and B cell-based cancers,” he says.
“Our vaccine-like immune response to the vaccine and treatment combination will hopefully reduce the disease burden on our patients, but it’s also important that we understand how to deliver the vaccine in a safe and efficacious way.”
The FDA approved Vertex’s vaccine in March, and it is scheduled to be available to the public later this year.
Verte announced the vaccine on May 1, saying that it would be “available by the end of this year” to patients with cancer and that it “will offer a rapid response to patients who are likely to need it.”
In the first phase of the trial, which will last about six months, Vertex hopes to recruit patients with two types of relapsers and two types, or relapsed relapserers, of relapsed T- or B-cell cancers.
The trial will initially focus on the patients who have relapsed and are not responding to other treatments.
Once the study is complete, Veritas hopes to enroll patients with a second type of relapseser and a third type of tumor, which it says will help determine whether VXOs vaccine can be used for a second group of patients with other types of cancers.
This type of trial is designed to determine whether the vaccine is safe, effective and safe for other people with the disease and is a long-term effort.
Smith says that Veritas’ vaccine is similar to one used in the National Institutes of Health (NIH) Cancer Vaccine Trials, which have been in clinical testing for about two decades.
“They’re the only vaccine that’s ever been approved for other than relapsering relapser disease,” he said.
“The vaccine is very similar to the immunotherapy vaccines that the NIH has been using in their trials, which are now in clinical trials and have shown to work.”
The NIH, which owns Vertex, is also working to develop a vaccine for people with lung cancer.
Smith said that this vaccine will likely be more expensive than the vaccine for T-and-B cell cancers.
“But we’re optimistic about this one, because it’s been very, very safe and well tolerated,” he adds.
“If you’re a patient with a tumor and you’re receiving chemotherapy, we’re also seeing the same benefit.
This vaccine is going to be a long time in coming.”
Vertex also plans to recruit people with liver and lung cancer to the trial and is also planning to enroll people with melanoma, ovarian cancer and multiple myeloma.
The vaccine is also expected to be more effective for people who have had other cancers treated.
“People who have cancer in their bodies, especially tumors, tend to have lower tumor-specific immune responses,” Smith says.
For people with cancer that’s already in remission, he says, the vaccine should